Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Charles Dharmani"'
Autor:
Charles Dharmani, Charles Kearns, Sudhir Unni, Yan Xiong, Maribel Salas, Nabil Said, Ngan Pham, Nazneen Fatimah Shaikh, Xiaoyu Zhou, Aimee Near
Publikováno v:
HemaSphere, Vol 7, p e88708fe (2023)
Externí odkaz:
https://doaj.org/article/da4be6bfe58e43d086af3fc080e509f2
Publikováno v:
Future Oncology. 19:159-171
Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demographics, comorbidities, survival and prognostic factors
Autor:
Charles Dharmani, Eric Wang, Maribel Salas, Colleen McCabe, Alvileen Diggs, Youngsook Choi, Jason Jiang, Vicki L Keedy
Publikováno v:
Future Oncology. 18:1595-1607
For drugs with enhanced serious safety risks, Risk Evaluation and Mitigation Strategy (REMS) may be required. Pexidartinib is approved for treatment of adult symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functio
Autor:
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, David Martínez-Cuadrón, Evelyn Acuña-Cruz, Laura Torres-Miñana, Rebeca Rodríguez-Veiga, Irene Navarro-Vicente, David Martínez-Campuzano, Raquel García-Ruiz, Pilar Lloret, Pedro Asensi, Ana Osa-Sáez, Jaume Aguero, María Rodríguez-Serrano, Francisco Buendía-Fuentes, Juan Eduardo Megías-Vericat, Beatriz Martín-Herreros, Eva Barragán, Claudia Sargas, Maribel Salas, Margaret Wooddell, Charles Dharmani, Miguel A. Sanz, Javier De la Rubia, Pau Montesinos
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2267
The incidence of cardiac morbimortality in acute myeloid leukemia (AML) is not well known. We aim to estimate the cumulative incidence (CI) of cardiac events in AML patients and to identify risk factors for their occurrence. Among 571 newly diagnosed
Publikováno v:
Clinical Drug Investigation. 37:1183-1190
This real-world study assessed the prevalence, risk factors for, and incidence of seizures in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC were selected from MarketScan Commercial and Medicare Supplementa
Autor:
Hal Li, Dominique Bertin, Thomas S. Hilzinger, Jeremy D. Jokinen, Peter Verdru, Charles Dharmani, Janet Hormbrey, Valerie Simmons, Bruce A. Donzanti, Karolyn Kracht
Publikováno v:
Therapeutic innovationregulatory science. 53(6)
Over the past decade, the volume of adverse events (AEs) reported to marketing authorization holders and regulators has been rapidly increasing each year, which has led to significant challenges in patient safety assessment. Three data sources that h
Publikováno v:
Developmental Medicine & Child Neurology. 45:508-514
Publikováno v:
Developmental Medicine & Child Neurology. 46
Publikováno v:
Developmental Medicine & Child Neurology. 45
The spectrum of language regression in childhood is incompletely understood. To describe the features of this disorder more fully, we reviewed the records of 196 consecutive children (143 males and 53 females) with language regression or perceived pl
Publikováno v:
Developmental Medicine & Child Neurology; Aug2003, Vol. 45 Issue 8, p508-514, 7p